176 related articles for article (PubMed ID: 923330)
1. Elimination of para-aminosalicylic acid in patients with liver disease and renal insufficiency.
Held H; Fried F
Chemotherapy; 1977; 23(6):405-15. PubMed ID: 923330
[TBL] [Abstract][Full Text] [Related]
2. P-aminosalicylate metabolism in cancer patients sensitive and resistant to chemotherapy.
Lavigne JG; Barry A; d'Auteuil C; Delage JM
Br J Cancer; 1977 May; 35(5):580-6. PubMed ID: 577182
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic evaluation of para-aminosalicylic acid granules.
Peloquin CA; Henshaw TL; Huitt GA; Berning SE; Nitta AT; James GT
Pharmacotherapy; 1994; 14(1):40-6. PubMed ID: 8159600
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
Kirch W; Rose I; Demers HG; Leopold G; Pabst J; Ohnhaus EE
Clin Pharmacokinet; 1987 Aug; 13(2):110-7. PubMed ID: 2887325
[TBL] [Abstract][Full Text] [Related]
5. A micro-method for the determination of paraaminosalicylic acid (aminosallyl) PAS and n-acetyl-para-aminosalicylic acid (acetyl-PAS).
NIELSEN E; PRAETORIUS E
Scand J Clin Lab Invest; 1952; 4(4):313-8. PubMed ID: 13048610
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance.
Adams KT; Donald PR; Abulfathi AA; Diacon AH; Stander MA; Reuter H
J Clin Pharmacol; 2020 Apr; 60(4):489-494. PubMed ID: 31682027
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics of isoniazid, PAS, and cycloserin in acute and chronic alcoholic intoxication (experimental study)].
Ortenberg ZA
Probl Tuberk; 1978 Sep; (9):60-4. PubMed ID: 568263
[No Abstract] [Full Text] [Related]
8. Brain regional pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite: effectiveness in chelating brain manganese.
Hong L; Jiang W; Pan H; Jiang Y; Zeng S; Zheng W
Drug Metab Dispos; 2011 Oct; 39(10):1904-9. PubMed ID: 21768272
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of the antituberculosis drugs.
Holdiness MR
Clin Pharmacokinet; 1984; 9(6):511-44. PubMed ID: 6391781
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.
Stoeckel K; Koup JR
Am J Med; 1984 Oct; 77(4C):26-32. PubMed ID: 6093514
[TBL] [Abstract][Full Text] [Related]
11. Influence of hepatic and renal disorders on the pharmacokinetics of sulfachloropyridacine.
Mariño EL; Dominguez-Gil A; Tabernero JM; Macias JG
Int J Clin Pharmacol Ther Toxicol; 1980 Jan; 18(1):10-4. PubMed ID: 7364528
[TBL] [Abstract][Full Text] [Related]
12. [Concentration and excretion of isoniazid and PAS in patients with tuberculosis depending on the functional status of the kidney].
Savula MM; Kiselova ES
Vrach Delo; 1978 May; (5):119-22. PubMed ID: 676253
[No Abstract] [Full Text] [Related]
13. Effect of sodium para-aminosalicylate on oxygen affinity in normal, sickle and fetal human blood.
Laasberg LH; Hedley-Whyte J; Laver MB
J Pharmacol Exp Ther; 1976 Nov; 199(2):441-53. PubMed ID: 10430
[TBL] [Abstract][Full Text] [Related]
14. Elimination and serum protein binding of phenylbutazone in patients with renal insufficiency.
Held H; Enderle C
Clin Nephrol; 1976 Sep; 6(3):388-93. PubMed ID: 136326
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and protein binding of cefpiramide in patients with alcoholic cirrhosis.
Demotes-Mainard F; Vinçon G; Amouretti M; Dumas F; Necciari J; Kieffer G; Begaud B
Clin Pharmacol Ther; 1991 Mar; 49(3):263-9. PubMed ID: 2007321
[TBL] [Abstract][Full Text] [Related]
16. HPLC analysis of para-aminosalicylic acid and its metabolite in plasma, cerebrospinal fluid and brain tissues.
Hong L; Jiang W; Zheng W; Zeng S
J Pharm Biomed Anal; 2011 Apr; 54(5):1101-9. PubMed ID: 21159459
[TBL] [Abstract][Full Text] [Related]
17. Plasma protein binding of clonazepam in hepatic and renal insufficiency and after hemodialysis.
Pacifici GM; Viani A; Rizzo G; Carrai M; Rane A
Ther Drug Monit; 1987 Dec; 9(4):369-73. PubMed ID: 3424402
[TBL] [Abstract][Full Text] [Related]
18. [Effect of various types of liver diseases on the behavior of cefoperazone].
Malè PJ; Dayer P; Châtelain G; Rudhardt M; Fabre J
Schweiz Med Wochenschr; 1983 Dec; 113(49):1860-3. PubMed ID: 6676938
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency.
Kirch W; Ohnhaus EE; Dylewicz P; Pabst J; Storstein L
Am Heart J; 1986 Feb; 111(2):325-9. PubMed ID: 3946177
[TBL] [Abstract][Full Text] [Related]
20. Renal failure after intravenous para-aminosalicylic acid administration in a case of intestinal and renal amyloidoidosis.
HAGELSTAM L; KUHLBACK B; RISKA N
Scand J Clin Lab Invest; 1963; 15 Suppl 69():62-9. PubMed ID: 13951868
[No Abstract] [Full Text] [Related]
[Next] [New Search]
